1. Home
  2. LNG vs ALNY Comparison

LNG vs ALNY Comparison

Compare LNG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$278.34

Market Cap

60.2B

Sector

Utilities

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$248.68

Market Cap

38.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
ALNY
Founded
1983
2002
Country
United States
United States
Employees
N/A
115
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2B
38.9B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
LNG
ALNY
Price
$278.34
$248.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
28
Target Price
$294.87
$471.00
AVG Volume (30 Days)
1.8M
1.6M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
0.82%
N/A
EPS Growth
69.93
206.88
EPS
N/A
2.71
Revenue
$19,976,000,000.00
$1,037,418,000.00
Revenue This Year
$16.48
$52.67
Revenue Next Year
$5.89
$31.48
P/E Ratio
N/A
$95.20
Revenue Growth
27.21
22.88
52 Week Low
$186.20
$197.81
52 Week High
$300.94
$495.55

Technical Indicators

Market Signals
Indicator
LNG
ALNY
Relative Strength Index (RSI) 51.51 49.94
Support Level $250.03 $223.61
Resistance Level $299.87 $314.04
Average True Range (ATR) 6.87 10.95
MACD -1.56 3.10
Stochastic Oscillator 19.30 50.35

Price Performance

Historical Comparison
LNG
ALNY

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquefied natural gas producer with two facilities in Corpus Christi, Texas, and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: